Literature DB >> 34815132

Small-diameter melanomas (micromelanomas): clinical, dermoscopic and histopathological findings.

Pablo Vargas-Mora1, Rubén González-Cuevas2, Leonardo Peruilh-Bagolini2, Fernando Valenzuela2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34815132      PMCID: PMC8802855          DOI: 10.1016/j.abd.2020.10.014

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


× No keyword cloud information.
Dear Editor, Melanoma is one of the cancers with the highest rates of increase in the last decades. Traditionally, mass education strategies have emphasized the importance of melanomas of > 6 mm (ABCDE rule).1, 2 However, the optimization of diagnostic methods, principally using dermoscopy, allows the early identification of melanomas smaller than this (micromelanomas). These may represent up to a third of all melanomas.3, 4, 5 For this reason, we decided to characterize the clinic, dermoscopy, and histopathology of micromelanomas in our institution. A retrospective study in the Dermatology Department of the Hospital Clínico de la Universidad de Chile, with all patients that had a diagnosis of cutaneous melanoma with a clinical diameter up to 5 mm, between January 1st, 2003, and December 31, 2018, were included. The following characteristics were evaluated: sex, age, location, clinical diameter, dermoscopy (evaluated by two dermoscopists separately) and clinical diagnosis, as well as histopathological characteristics such as diagnosis (in situ or invasive), Breslow Index (BI), and ulceration. Descriptive statistics were applied using absolute numbers, percentages, averages, and standard deviation. A total of 20 patients were evaluated (Table 1), 15 women (75%), and the mean age was 50.4 years (±13.4; range 28–79 years). The most common location was the lower limbs (9/20), followed by the head/neck (5/20), trunk (4/20), and upper limbs (2/20). The mean clinical diameter was 3.7 mm (±1.0; range 2–5 mm). The most frequent clinical diagnosis was atypical nevus (9/20), followed by melanocytic nevus (5/20), melanoma (5/20), and seborrheic keratosis (1/20). There was a photographic record of dermoscopy as much as twelve lesions, and an atypical network pattern was found in 6/12 (Fig. 1A and B), followed by irregular dots/globules (3/12), irregular hyperpigmented areas (3/12), and atypical blotches (2/12) (Fig. 2A and B). From the histopathological study: 12 cases (60%) showed in situ melanomas and the other 8 (40%) invasive melanomas, with a BI between 0.25 and 2.8 mm. None of the lesions showed ulceration. In two cases sentinel node biopsy was carried out, with negative results.
Table 1

Clinical, dermatoscopic and histopathological features of micromelanomas (n = 20).

CaseSex/ageClinical diagnosisLocationSize (mm)Histopathological diagnosisBreslow index (mm)Dermoscopy: main patternDermoscopy: melanoma criteria
1F/44Atypical nevusTrunk4In situN/AReticularAN, IHA
2F/45Atypical nevusUpper limbs4In situN/AReticularAN, IG
3M/72Atypical nevusTrunk4Invasive0.75MulticomponentTSA, AB, SWS
4F/45MelanomaLower limbs2In situN/AN/RN/R
5M/44MelanomaLower limbs3Invasive1.2N/RN/R
6F/50NevusLower limbs5Invasive0.25ReticularAN
7F/60MelanomaHead/neck3In situN/AReticularAN
8M/52Intradermal nevusHead/neck5Invasive2.8N/RN/R
9F/61NevusHead/neck3In situN/AN/RN/R
10M/50MelanomaHead/neck5Invasive0.9ReticularAN
11F/79NevusHead/neck2Invasive0.8N/RN/R
12F/30Atypical nevusLower limbs3In situN/AN/RN/R
13F/40Atypical nevusUpper limbs3In situN/AGlobularIG
14F/28Atypical nevusLower limbs5In situN/ABicomponentaIHA
15F/36Seborrheic keratosisTrunk5Invasive0.7N/RN/R
16F/68Atypical nevusLower limbs3Invasive0.4StructurelessAB
17F/44Atypical nevusLower limbs3In situN/AReticularAN
18F/46Atypical nevusLower limbs3In situN/AN/RN/R
19M/64NevusTrunk5In situN/ABicomponentaIG
20F/50MelanomaLower limbs4In situN/ABicomponentaIHA

F, Female; M, Male; N/A, Not Applicable; N/R, Not Registered; AN, Atypical Network; TSA, Tan Structureless Areas; AB, Atypical Blotches; IG, Irregular dots/Globules; SWS, Shiny White Structures; IHA, Irregular Hyperpigmented Areas.

Bicomponent with the reticular pattern associated.

Figure 1

(A), In situ melanoma. Clinical diameter of 4 mm. (B), Dermoscopy shows an atypical network with irregular hyperpigmented areas.

Figure 2

(A), Invasive melanoma of 0.75 mm in Breslow thickness with a diameter of 3 mm. (B), Dermoscopy shows a multi-component pattern with tan structureless areas, atypical blotch, shiny white structures, and serpentine vessels.

Clinical, dermatoscopic and histopathological features of micromelanomas (n = 20). F, Female; M, Male; N/A, Not Applicable; N/R, Not Registered; AN, Atypical Network; TSA, Tan Structureless Areas; AB, Atypical Blotches; IG, Irregular dots/Globules; SWS, Shiny White Structures; IHA, Irregular Hyperpigmented Areas. Bicomponent with the reticular pattern associated. (A), In situ melanoma. Clinical diameter of 4 mm. (B), Dermoscopy shows an atypical network with irregular hyperpigmented areas. (A), Invasive melanoma of 0.75 mm in Breslow thickness with a diameter of 3 mm. (B), Dermoscopy shows a multi-component pattern with tan structureless areas, atypical blotch, shiny white structures, and serpentine vessels. The present study is the first series of micromelanomas in Latin American patients. We point out the high percentage of invasive melanomas, including one case with a BI over 2 mm. This is similar to that shown in other studies which have reported between 27% and 45% invasive melanomas.1, 3, 6 However, Bono et al., reported an invasive component in 19 of their 23 lesions of 3 mm or less (83%). This is highly noteworthy and worrying, given that it contrasts with classical thinking which suggests that small lesions are early-stage lesions. Strategies for the early detection of melanomas, like the ABCDE rule, are not very efficient for recognizing micromelanomas. A clinical characteristic suggested by several authors is the greater frequency and intensity of black coloration. This suggests the possibility of changing the ABCDE rule, with ‘Dark’ replacing ‘Diameter’ as the letter ‘D’ for these lesions. However, it should be noted the poor utility of this rule in nodular melanomas, which may represent an important part of thicker micromelanomas. As for the dermoscopy, we observed a more frequent atypical network, irregular dots/globules, and irregular hyperpigmented areas, as described in the literature.3, 7 According to Seidenari et al., micromelanomas lack many of the characteristics that larger lesions have, as they are less asymmetrical, have fewer colors, and have a lower frequency of a regression. They also have practically no atypical vessels or blue-white veil, and this undoubtedly makes diagnosis more difficult. Small diameter melanocytic lesions should be evaluated in the same way as larger lesions, because if they turn out to be melanomas the possibility, they will be invasive is not low, as our study shows.

Financial support

None declared.

Authors’ contributions

Pablo Vargas-Mora: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the literature; critical review of the manuscript. Rubén González-Cuevas: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the literature; critical review of the manuscript. Leonardo Peruilh-Bagolini: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the manuscript. Fernando Valenzuela: Approval of the final version of the manuscript; conception and planning of the study; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the manuscript.

Conflicts of interest

None declared.
  7 in total

1.  Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm.

Authors:  A Bono; E Tolomio; S Trincone; C Bartoli; S Tomatis; A Carbone; M Santinami
Journal:  Br J Dermatol       Date:  2006-09       Impact factor: 9.302

2.  Dermoscopy features of melanomas with a diameter up to 5 mm (micromelanomas): A retrospective study.

Authors:  Aphrodite Megaris; Aimilios Lallas; Leonardo Peruilh Bagolini; George Balais; Ruben González Cuevas; Konstantinos Lallas; Theodosia Gkentsidi; Sofia-Magdalini Manoli; Chryssoula Papageorgiou; Ioannis Spyridis; Zoe Apalla
Journal:  J Am Acad Dermatol       Date:  2020-04-11       Impact factor: 11.527

3.  Micromelanomas identified with time-lapse total body photography and dermoscopy.

Authors:  Elizabeth D Drugge; Elgida R Volpicelli; Rebecca M Sarac; Sophie R Strang; Dirk M Elston; Rhett J Drugge
Journal:  J Am Acad Dermatol       Date:  2018-01       Impact factor: 11.527

4.  Dermoscopy of small melanomas: just miniaturized dermoscopy?

Authors:  S Seidenari; C Ferrari; S Borsari; A Fabiano; S Bassoli; F Giusti; G Ponti; C Magnoni
Journal:  Br J Dermatol       Date:  2014-06-11       Impact factor: 9.302

Review 5.  Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.

Authors:  Naheed R Abbasi; Helen M Shaw; Darrell S Rigel; Robert J Friedman; William H McCarthy; Iman Osman; Alfred W Kopf; David Polsky
Journal:  JAMA       Date:  2004-12-08       Impact factor: 56.272

6.  A series of melanomas smaller than 4 mm and implications for the ABCDE rule.

Authors:  S M Goldsmith; A R Solomon
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-08       Impact factor: 6.166

7.  A tiny invasive melanoma: a case report with dermatoscopy and dermatopathology.

Authors:  Gary Pellizzari; Jill Magee; David Weedon; Cliff Rosendahl
Journal:  Dermatol Pract Concept       Date:  2013-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.